# Trial of Therapies With IT cDC1s Combined w/ IT Trastuzamab for Her+ or IT Nivolumab for Her- BC LMD

> **NCT07694986** · PHASE2 · RECRUITING · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 30 (estimated)

## Conditions studied

- Breast Cancer
- Leptomeningeal Disease

## Interventions

- **BIOLOGICAL:** cDC1 Vaccine
- **DRUG:** Trastuzumab
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT07694986
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2029-08
- **Final completion:** 2030-08
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-07-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07694986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07694986, "Trial of Therapies With IT cDC1s Combined w/ IT Trastuzamab for Her+ or IT Nivolumab for Her- BC LMD". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07694986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*